NTRA, US6323071042

Natera stock: On Xetra, Natera stock rises 3.03 percent

Published on 10/21/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Natera reports third-quarter results on November 5, 2026 after close. Natera stock costs EUR 370.90 on October 21, 2026, up 3.03 percent versus the Xetra close.

Price move and reporting date

  • Natera stock rose 3.03 percent on October 21, 2026.
  • Natera is expected to report third-quarter results on November 5, 2026, after the close.
  • Natera stock costs EUR 370.90 at Lang & Schwarz on October 21, 2026 at 4:32 p.m. CEST, 3.03 percent above the Xetra close of October 19, 2026.
NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) rose 3.03 percent against the Xetra close of October 19, 2026, putting the diagnostics company at EUR 370.90 at Lang & Schwarz on October 21, 2026 at 4:32 p.m. CEST. The company is expected to report third-quarter results on November 5, 2026, after the close, according to Gekko.

November 5 sets the next date

The scheduled report gives investors a defined checkpoint after Natera's second-quarter revenue reached USD 752.75 million for the period ended June 30, 2026. The figure was 37.70 percent higher than in the prior-year quarter, while diluted earnings per share were minus USD 0.47. Natera's investor-relations page describes the company as a provider of cell-free DNA testing across women's health, oncology and organ health.

Natera says its platform includes Panorama, Signatera and Prospera. The June 30, 2026 balance sheet showed total assets of USD 2.66 billion, while operating cash flow was USD 54.79 million in the second quarter.

Stock stays below its yearly high

The Nasdaq price was USD 416.43 at 2:35 p.m. UTC on October 21, 2026, with a market capitalization of USD 60.0 billion. Its 52-week range was USD 181.00 to USD 437.41, leaving the price 4.80 percent below the high. The quote was up 2.59 percent from the prior Nasdaq close.

For valuation context, Bernstein reiterated a Buy rating and a USD 365 target on October 19, 2026, according to Gekko. The target sits USD 51.43 below the Nasdaq price cited above. The same page listed 21 firms with an average 12-month target of USD 403.89.

What comes after the results date?

The November 5 report will put the USD 707.70 million consensus revenue estimate against the USD 752.75 million achieved in the second quarter, according to Gekko. That comparison matters because the latest quarterly revenue growth was 37.70 percent, while the company continued to post a net loss of USD 66.97 million in the same period.

Price holds above the Xetra close

Natera stock was trading at EUR 370.90 at Lang & Schwarz on October 21, 2026 at 4:32 p.m. CEST, 3.03 percent above the Xetra close of October 19, 2026 at EUR 360.00. The further course of trading is shown by the continuously updated real-time quote of Natera stock.

Natera stock facts

  • Company: Natera, Inc.
  • ISIN: US6323071042
  • Ticker: NTRA
  • Primary exchange: Nasdaq
  • Price Lang & Schwarz (as of October 21, 2026, 4:32 p.m. CEST): EUR 370.90
  • Change versus Xetra close: plus 3.03 percent
  • Xetra close (October 19, 2026): EUR 360.00
  • Market capitalization: USD 60.0 billion (as of October 21, 2026)
  • 52-week range: USD 181.00-437.41 (as of October 21, 2026)
  • Sector / Industry: Health technology / Biotechnology
  • Next earnings date: November 5, 2026

Market context: Market report S&P 500.

More news and analyses on Natera stock

Disclaimer...
en | US6323071042 | NTRA | boerse | 70385388 | bgmi